150 related articles for article (PubMed ID: 18230757)
1. Human antibody RNase fusion protein targeting CD30+ lymphomas.
Menzel C; Schirrmann T; Konthur Z; Jostock T; Dübel S
Blood; 2008 Apr; 111(7):3830-7. PubMed ID: 18230757
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
[TBL] [Abstract][Full Text] [Related]
3. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
4. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
[TBL] [Abstract][Full Text] [Related]
5. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
6. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.
Stöcker M; Tur MK; Sasse S; Krüssmann A; Barth S; Engert A
Protein Expr Purif; 2003 Apr; 28(2):211-9. PubMed ID: 12699683
[TBL] [Abstract][Full Text] [Related]
7. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
Matthey B; Engert A; Barth S
Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
[TBL] [Abstract][Full Text] [Related]
8. From immunotoxins to immunoRNases.
De Lorenzo C; D'Alessio G
Curr Pharm Biotechnol; 2008 Jun; 9(3):210-4. PubMed ID: 18673286
[TBL] [Abstract][Full Text] [Related]
9. Antibody fusion proteins with human ribonucleases 1 to 8.
Wezler X; Dübel S; Schirrmann T
Hum Antibodies; 2018; 26(4):177-192. PubMed ID: 29689715
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
Hansen HP; Matthey B; Barth S; Kisseleva T; Mokros T; Davies SJ; Beckett RP; Foelster-Holst R; Lange HH; Engert A; Lemke H
Int J Cancer; 2002 Mar; 98(2):210-5. PubMed ID: 11857410
[TBL] [Abstract][Full Text] [Related]
11. Human antibodies targeting CD30(+) lymphomas.
Wezler X; Hust M; Helmsing S; Schirrmann T; Dübel S
Hum Antibodies; 2012; 21(1-2):13-28. PubMed ID: 22885957
[TBL] [Abstract][Full Text] [Related]
12. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapeutic RNases (ImmunoRNases).
Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
[TBL] [Abstract][Full Text] [Related]
14. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
[TBL] [Abstract][Full Text] [Related]
15. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
16. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
[TBL] [Abstract][Full Text] [Related]
17. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.
Hursey M; Newton DL; Hansen HJ; Ruby D; Goldenberg DM; Rybak SM
Leuk Lymphoma; 2002 May; 43(5):953-9. PubMed ID: 12148905
[TBL] [Abstract][Full Text] [Related]
18. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
19. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
